SONUÇ VE ÖNERİLER

Şizofreni ve Şizoafektif Bozukluk hastalarında kesitsel bulgular incelendiğinde MetS varlığı ile kısa psikiyatrik yatış süresi; ailede kanser öyküsü;

UKU toplam puanındaki yükseklik; yüksek günlük şeker, kolesterol, omega-3 yağ asidi ve ÇDYA alımı arasında ilişki olduğu saptanmıştır.

Sekiz yıllık izlemde MetS yaygınlığının arttığı görülmüştür. Bu artışın genel nüfusla ilgili yayınlanan çalışmalarda MetS bileşenlerindeki artışa paralel olduğu düşünülmüştür. Metabolik Sendrom değişim grupları incelendiğinde MetS yaygınlığındaki artışın sosyodemografik özellikler, sigara kullanımı, antipsikotik tedavi özellikleri ve toplam doz, valproik asit kullanımı ile ilişkili olmadığı saptanmıştır. Yeni gelişen MetS vakalarında günlük şeker alımının, şeker alımının günlük enerji alımına oranının ve günlük ÇDYA alımının yüksek olduğu saptanmıştır.

Ölüm oranlarına bakıldığında da KVH nedenli ölümlerin çoğunluğu oluşturduğu görülmektedir.

Şizofrenide MetS yaygınlığı ve yordayıcıları ile ilgili 1 yıldan daha uzun süreli izlem çalışmalarına gereksinim vardır. Metabolik Sendrom sıklığının daha yüksek olduğu ilk rahatsızlık dönemindeki veya kronik olmayan hastaların alınacağı izleme çalışmaları şizofrenide MetS ile ilişkili etmenlerin daha iyi anlaşılmasına yardım edecektir. Antipsikotik ilaçların türü ve dozları ile beslenme ve fiziksel aktivite özelliklerinin daha sık ve ayrıntılı olarak inceleneceği bu çalışmalarla MetS gelişmesine katkıda bulunan etmenlerin yanı sıra değişik ilaç ve hayat tarzı müdahalelerinin etkisi de daha iyi gösterilebilecektir.

KAYNAKLAR

1. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet. 2005;

366: 1059–1062.

2. American Diabetes Association, American Psychiatric Association.

Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care February 2004 vol. 27 no. 2 596-601

3. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th edition). Washington, DC.

4. Bey L, Hamilton MT. Suppression of skeletal muscle lipoprotein lipase activity during physical inactivity: a molecular reason to maintain daily low-intensity activity. J Physiol. 2003 Sep 1;551(Pt 2):673-82.

5. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J;

CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007 Feb;90(1-3):162-73.

6. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J;

CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics:

results from the CLAMORS study. Eur Psychiatry. 2012 May;27(4):267-74.

7. Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR.: Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med. 2008;38(1):103-12.

8. Cerit C, Ozten E, Yildiz M.: The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turk Psikiyatri Derg. 2008 Summer;19(2):124-32.

9. Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids. 2001 Sep;36(9):937-44.

10. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res.

2007 Jan;89(1-3):91-100.

11. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008 Nov;10(7):788-97.

12. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006 Apr;67(4):575-83.

13. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95.

14. De Hert M, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, Falissard B. The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I.

Methodology. Int J Methods Psychiatr Res. 2010 Dec;19(4):195-210.

15. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report. 2009 May 5;(13):1-7.

16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97.

17. Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M.:Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, Davis S, Stroup TS, Swartz M, Lieberman J, Rosenheck R. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res. 2011 May;128(1-3):166-70. Epub 2011 Feb 21.

18. Grundy SM, Cleeman JI, Bairey Merz CN, et al, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.

19. Hanley AJ1, Karter AJ, Williams K, Festa A, D'Agostino RB Jr, Wagenknecht LE, Haffner SM. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation. 2005 Dec 13;112(24):3713-21.

20. Hansen T1, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O, Jakobsen KD, Rasmussen HB, Tosato S, Rietschel M, Frank J, Owen M, Bonetto C, Suvisaari J, Thygesen JH, Pétursson H, Lönnqvist J, Sigurdsson E, Giegling I, Craddock N, O'Donovan MC, Ruggeri M, Cichon S, Ophoff RA, Pietiläinen O, Peltonen L, Nöthen MM, Rujescu D, St Clair D, Collier DA, Andreassen OA, Werge T. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry. 2011 Jul 1;70(1):59-63.

21. Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, Davis S, Stroup TS, Swartz M, Lieberman J, Rosenheck R. The association between weight change and symptom reduction in the CATIE schizophrenia trial.

Schizophr Res. 2011 May;128(1-3):166-70.

22. Kang SH, Kim KH, Kang GY, Lee KH, Kim KK, Soh M, Ahn KJ, Kim SH, Lee JI. Cross-sectional prevalence of metabolic syndrome in Korean patients with schizophrenia. Schizophr Res. 2011 May;128(1-3):179-81.

23. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.

24. Kaya MC, Virit O, Altındag˘ A, Selek S, Bulbul F, Bulut M, Savas¸ HA (2009) Prevalence of metabolic syndrome, characteristics of metabolic syndrome and relationship with the antipsychotics used in schizophrenia.

Arch Neuropsychiatry 46:13–18

25. Kostakoğlu AE (1998) Şizofrenik hastalarda olanzapin ve klorpromazinin etki ve emniyetinin karşılaştırılması. Hacettepe Üniversitesi Tıp Fakültesi Psikiyatri Anabilim Dalı, Uzmanlık Tezi, Ankara.

26. Kostakoğlu AE, Batur S., Tiryaki A ve ark. Pozitif ve negatif sendrom ölçeğinin (PANSS) Türkçe uyarlamasının geçerlilik ve güvenilirliği. Türk Psikoloji Dergisi 1999;14:22-23

27. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, Celik S.:

Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr. 2007 Apr;61(4):548-53. Epub 2006 Nov 22.

28. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4;288(21):2709-16.

29. L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN.: Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry. 2007 Oct;68(10):1510-6.

30. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.

Acta Psychiatr Scand Suppl. 1987;334:1-100.

31. Malhotra N, Grover S, Chakrabarti S, Kulhara P. Metabolic syndrome in schizophrenia. Indian J Psychol Med. 2013 Jul;35(3):227-40.

32. McEvoy JP1, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005 Dec 1;80(1):19-32.

33. Meltzer HY, Bonaccorso S, Bobo WV, Chen Y, Jayathilake K. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. J Clin Psychiatry. 2011 Dec;72(12):1602-10.

34. Merdol Kutluay, T. (2003). Toplu Beslenme Yapılan Kurumlar İçin Standart Yemek Tarifeleri. Ankara: Hatipoğlu Yayınevi.

35. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA.

Change in metabolic syndrome parameters with antipsychotic treatment in

the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008 Apr;101(1-3):273-86. Epub 2008 Feb 6.

36. Onat A, Hergenç G, Can G.: Prospective validation in identical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition. Anadolu Kardiyol Derg. 2007 Mar;7(1):29-34.

37. Oyekcin DG (2009) The frequency of metabolic syndrome in patients with schizophrenia and schizoaffective disorder. Anatolian J Psychiatry 10:26–33 38. Ozsahin AK, Gokcel A, Sezgin N, Akbaba M, Guvener N, Ozisik L, Karademir BM.: Prevalence of the metabolic syndrome in a Turkish adult population. Diabetes Nutr Metab. 2004 Aug;17(4):230-4.

39. Raedler TJ.: Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry.

2010 Nov;23(6):574-81.

40. Rakıcıoğlu, N., Tek Acar, N., Ayaz, A., Pekcan, G. (2009). Yemek ve Besin Fotoğraf Kataloğu-Ölçü Miktarlar. Ankara: Ata Ofset Matbaacılık.

41. Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull. 2004;30(4):901-11.

42. Riccardi G, Giacco R, Rivellese AA. Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr. 2004 Aug;23(4):447-56.

43. Roffeei SN, Mohamed Z, Reynolds GP, Said MA, Hatim A, Mohamed EH, Aida SA, Zainal NZ. Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. Pharmacogenomics. 2014 Mar;15(4):477-85.

44. Saglam M, Arikan H, Savci S, Inal-Ince D, Bosnak-Guclu M, Karabulut E, Tokgozoglu L. International physical activity questionnaire: reliability and validity of the Turkish version. Percept Mot Skills. 2010 Aug;111(1):278-84.

45. Saiki A, Oyama T, Endo K, Ebisuno M, Ohira M, Koide N, Murano T, Miyashita Y, Shirai K. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract. 2007 Apr;76(1):93-101.

46. Sanisoglu SY, Oktenli C, Hasimi A, Yokusoglu M, Ugurlu M.: Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. BMC Public Health. 2006 Apr 10;6:92.

47. Sarısoy G, Böke Ö, Öztürk A, Akkaya D, Pazvantoğlu O, Şahin AR.

Şizofreni hastalarında metabolik sendrom sıklığının sosyodemografik ve klinik özelliklerle ilişkisi. Düşünen Adam: Psikiyatri ve Nörolojik Bilimler Dergisi 2013;26:267-275

48. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J;

TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013 Feb;28(2):169-80.

49. Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, Bastar I, Tütüncü Y, Sargin M, Dinççag N, Karsidag K, Kalaça S, Ozcan C, King H.

Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes Care. 2002 Sep;25(9):1551-6.

50. Schorr SG, Slooff CJ, Bruggeman R, Taxis K.: Prevalence of metabolic syndrome in patients with psychotic disorders in the Netherlands. J Clin Psychopharmacol. 2009 Aug;29(4):399-402.

51. Shi L, Ascher-Svanum H, Chiang YJ, Zhao Y, Fonseca V, Winstead D.

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry. 2009 Dec 18;9:80.

52. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH.: Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med. 2007 May;24(5):481-5. Epub 2007 Mar 22.

53. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry. 2007 Apr 23;7:14.

54. Sugawara N, Yasui-Furukori N, Sato Y, Kishida I, Yamashita H, Saito M, Furukori H, Nakagami T, Hatakeyama M, Kaneko S. Comparison of

prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia. Ann Gen Psychiatry. 2011 Sep 12;10:21.

55. Tokgözoğlu L, Bariş Kaya E.: Atherosclerotic vascular disease and risk factors in Turkey: from past to present. J Atheroscler Thromb. 2008 Dec;15(6):286-91. Epub 2008 Dec 9.

56. Tokgözoğlu SL.:The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey.

Eur Arch Psychiatry Clin Neurosci. 2011 Feb;261(1):69-78. Epub 2010 Jun 3.

57. Vancampfort D1, Knapen J, Probst M, Scheewe T, Remans S, De Hert M. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 2012 May;125(5):352-62.

58. Vancampfort D1, Knapen J, Probst M, van Winkel R, Deckx S, Maurissen K, Peuskens J, De Hert M. Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia.

Psychiatry Res. 2010 May 30;177(3):271-9.

59. Vancampfort D1, Sweers K, Probst M, Maurissen K, Knapen J, Minguet P, De Hert M. Association of the metabolic syndrome with physical activity performance in patients with schizophrenia. Diabetes Metab. 2011 Sep;37(4):318-23.

60. Vessby B, Uusitupa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC, Nälsén C, Berglund L, Louheranta A, Rasmussen BM, Calvert GD, Maffetone A, Pedersen E, Gustafsson IB, Storlien LH; KANWU Study.

Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia.

2001 Mar;44(3):312-9.

61. Yang L, Chen J, Liu D, Yu S, Cong E, Li Y, Wu H, Yue Y, Zuo S, Wang Y, Liang S, Shi Y, Shi S, Xu Y. Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jan 2;56:136-41.

62. Yazici MK, Anil Yağcioğlu AE, Ertuğrul A, Eni N, Karahan S, Karaağaoğlu E, Tokgözoğlu SL. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey.

Eur Arch Psychiatry Clin Neurosci. 2011 Feb;261(1):69-78.

63. Zhu S, St-Onge MP, Heshka S, Heymsfield SB.

Lifestyle behaviors associated with lower risk of having the metabolic syndrome. Metabolism. 2004 Nov;53(11):1503-11.

EKLER Ek 1.

Araştırma Amaçlı Çalışma İçin Aydınlatılmış Onam Formu

Ek 8.

24 saatlik besin tüketimi örnek kayıt

Besin Miktar Enerji Karb.h.

__________________________________________________________________

____________

KAHVALTI

Domates 35 g 6,1 kcal 0,9 gr beyaz peynir (y) 30 g 122,4 kcal 0,0 gr siyah zeytin 12,5 g 44,2 kcal 0,6 gr beyaz ekmek 25 g 63,9 kcal 13,2 gr şeker 6 g 24,3 kcal 6,0 gr ARA ÖĞÜN

ÖĞLE YEMEĞİ

tarhana (kuru) 15 g 49,8 kcal 9,6 gr ayçiçek yağı 5 g 44,1 kcal 0,0 gr beyaz lahana 30 g 7,5 kcal 1,2 gr beyaz pirinç 30 g 104,7 kcal 23,3 gr kurusoğan 30 g 8,4 kcal 1,5 gr ayçiçek yağı 10 g 88,3 kcal 0,0 gr domates 75 g 13,1 kcal 1,9 gr kurusoğan 45 g 12,6 kcal 2,2 gr yeşil/dolmalık biber 15 g 3,0 kcal 0,4 gr maydanoz 7,5 g 3,9 kcal 0,6 gr dana kıyması 75 g 151,6 kcal 0,3 gr pide/lavaş/bazlama çeş. 140 g 329,6 kcal 67,3 gr yoğurt (ty) 150 g 98,6 kcal 6,0 gr ARA ÖĞÜN

AKŞAM YEMEĞİ

tarhana (kuru) 15 g 49,8 kcal 9,6 gr ayçiçek yağı 5 g 44,1 kcal 0,0 gr beyaz kuru fasulye 50 g 131,6 kcal 19,9 gr kurusoğan 15 g 4,2 kcal 0,7 gr sucuk (y) 50 g 165,4 kcal 2,6 gr ayçiçek yağı 7,5 g 66,2 kcal 0,0 gr domates salçası 3 g 2,2 kcal 0,4 gr bulgur 50 g 162,6 kcal 34,5 gr kurusoğan 15 g 4,2 kcal 0,7 gr ayçiçek yağı 10 g 88,3 kcal 0,0 gr pazı 70 g 17,7 kcal 2,0 gr ayçiçek yağı 5 g 44,1 kcal 0,0 gr kayısı (kuru) 30 g 74,9 kcal 15,1 gr şeker 40 g 162,2 kcal 39,9 gr Ek 8. (Devam)

24 saatlik besin tüketimi örnek kayıt (Devamı)

AKŞAM YEMEĞİNDEN SONRA

Elma 285 g 147,8 kcal 32,6 gr Mandalin 100 g 50,2 kcal 10,1 gr

Ek 9.

BEBİS yazılımından elde edilen örnek bir sonuç çıktısı